Safety and clinical effectiveness of <scp>iGlarLixi</scp> in people with type 2 diabetes mellitus in Mexico
iGlarLixi demonstrated a consistent safety profile aligned with findings from previous randomised controlled trials. The most common ADRs were gastrointestinal disorders that were generally tolerable. Over 50% of participants treated with iGlarLixi achieved their glycaemic targets.
Authors
- Juan Rosas-Guzmán
- María Elena Sañudo‐Maury (ORCID: https://orcid.org/0000-0002-8463-462X)
- Luis Anguiano
- Leobardo Sauque‐Reyna (ORCID: https://orcid.org/0000-0003-4353-5753)
- Alberto Navarro‐Lara
Institutions
- Sanofi (Mexico) (MX)
- University of Celaya (MX)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1111/dom.16357
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Sanofi